Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole

Chiyo Imamura; Kenichi Furihata; Shinichiro Okamoto; Yusuke Tanigawara

doi:10.1002/jcph.605

Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole

Chiyo Imamura, Kenichi Furihata, Shinichiro Okamoto, Yusuke Tanigawara

研究成果: Article

17 引用（Scopus）

抜粋

This study evaluated the effects of cytochrome P450 (CYP) 2C19 polymorphisms on tacrolimus pharmacokinetics when coadministered with voriconazole. Eighteen healthy volunteers, including 6 individuals in each CYP2C19 genotype (extensive metabolizers [EMs], intermediate metabolizers [IMs], and poor metabolizers [PMs]), received a single oral dose of 3 mg tacrolimus alone or in combination with 200 mg voriconazole twice daily at steady state. When tacrolimus was coadministered with voriconazole, a significant increase in area under its concentration-time curve (AUC_0-24) was observed for all genotypes. AUC_0-12 of voriconazole in IMs and PMs were significantly higher than that in EMs (P 0-24 of tacrolimus in combination with voriconazole in IMs and PMs were also significantly higher than that in EMs (P

元の言語	English
ページ（範囲）	408-413
ページ数	6
ジャーナル	Journal of Clinical Pharmacology
巻	56
発行部数	4
DOI	https://doi.org/10.1002/jcph.605
出版物ステータス	Published - 2016 4 1

フィンガープリント

ASJC Scopus subject areas

Pharmacology (medical)
Pharmacology

これを引用

Imamura, C., Furihata, K., Okamoto, S., & Tanigawara, Y. (2016). Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. Journal of Clinical Pharmacology, 56(4), 408-413. https://doi.org/10.1002/jcph.605

@article{790065243cc64a46a4abc902108eea6a,

title = "Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole",

abstract = "This study evaluated the effects of cytochrome P450 (CYP) 2C19 polymorphisms on tacrolimus pharmacokinetics when coadministered with voriconazole. Eighteen healthy volunteers, including 6 individuals in each CYP2C19 genotype (extensive metabolizers [EMs], intermediate metabolizers [IMs], and poor metabolizers [PMs]), received a single oral dose of 3 mg tacrolimus alone or in combination with 200 mg voriconazole twice daily at steady state. When tacrolimus was coadministered with voriconazole, a significant increase in area under its concentration-time curve (AUC0-24) was observed for all genotypes. AUC0-12 of voriconazole in IMs and PMs were significantly higher than that in EMs (P 0-24 of tacrolimus in combination with voriconazole in IMs and PMs were also significantly higher than that in EMs (P ",

keywords = "CYP2C19 polymorphism, CYP3A, drug interaction, tacrolimus, voriconazole",

author = "Chiyo Imamura and Kenichi Furihata and Shinichiro Okamoto and Yusuke Tanigawara",

year = "2016",

month = apr

day = "1",

doi = "10.1002/jcph.605",

language = "English",

volume = "56",

pages = "408--413",

journal = "Journal of Clinical Pharmacology",

issn = "0091-2700",

publisher = "SAGE Publications Inc.",

number = "4",

}

TY - JOUR

T1 - Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole

AU - Imamura, Chiyo

AU - Furihata, Kenichi

AU - Okamoto, Shinichiro

AU - Tanigawara, Yusuke

PY - 2016/4/1

Y1 - 2016/4/1

N2 - This study evaluated the effects of cytochrome P450 (CYP) 2C19 polymorphisms on tacrolimus pharmacokinetics when coadministered with voriconazole. Eighteen healthy volunteers, including 6 individuals in each CYP2C19 genotype (extensive metabolizers [EMs], intermediate metabolizers [IMs], and poor metabolizers [PMs]), received a single oral dose of 3 mg tacrolimus alone or in combination with 200 mg voriconazole twice daily at steady state. When tacrolimus was coadministered with voriconazole, a significant increase in area under its concentration-time curve (AUC0-24) was observed for all genotypes. AUC0-12 of voriconazole in IMs and PMs were significantly higher than that in EMs (P 0-24 of tacrolimus in combination with voriconazole in IMs and PMs were also significantly higher than that in EMs (P

AB - This study evaluated the effects of cytochrome P450 (CYP) 2C19 polymorphisms on tacrolimus pharmacokinetics when coadministered with voriconazole. Eighteen healthy volunteers, including 6 individuals in each CYP2C19 genotype (extensive metabolizers [EMs], intermediate metabolizers [IMs], and poor metabolizers [PMs]), received a single oral dose of 3 mg tacrolimus alone or in combination with 200 mg voriconazole twice daily at steady state. When tacrolimus was coadministered with voriconazole, a significant increase in area under its concentration-time curve (AUC0-24) was observed for all genotypes. AUC0-12 of voriconazole in IMs and PMs were significantly higher than that in EMs (P 0-24 of tacrolimus in combination with voriconazole in IMs and PMs were also significantly higher than that in EMs (P

KW - CYP2C19 polymorphism

KW - CYP3A

KW - drug interaction

KW - tacrolimus

KW - voriconazole

UR - http://www.scopus.com/inward/record.url?scp=84960100931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960100931&partnerID=8YFLogxK

U2 - 10.1002/jcph.605

DO - 10.1002/jcph.605

M3 - Article

C2 - 26239045

AN - SCOPUS:84960100931

VL - 56

SP - 408

EP - 413

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 4

ER -

文献にアクセス

10.1002/jcph.605